Day One 股价在 Servier 25 亿美元收购后飙升 65%

关键事实

1Servier agreed to acquire Day One Biopharmaceuticals for $21.50 per share in cash.

2The total equity value of the transaction is approximately $2.5 billion.

3The deal is expected to close in the second quarter of 2026, subject to customary conditions.

法国制药集团 Servier 已达成最终协议，将以每股 21.50 美元的价格，通过总价值 25 亿美元的全现金交易收购 Day One Biopharmaceuticals (DAWN)。消息公布后，Day One 股价周五上午飙升 65%，较其前一收盘价溢价近 70%。受益于显著的收购溢价，该股目前交易价格是其 2026 年初价格的两倍多。市场分析师认为这笔交易是对 Day One 核心项目 Ojemda (tovorafebin) 的重大认可，该项目是一种治疗儿童低级别胶质瘤的突破性疗法。这一战略举措使 Servier 能够显著增强其全球肿瘤产品组合以及罕见儿科疾病管线。该交易预计将于 2026 年第二季度完成，尚待获得惯例监管批准和股东同意。

免费注册以访问此内容

创建免费账户

版本历史

版本 120 days ago

变更内容: Updated the story to include the 65% stock surge, the 70% premium details, and identified the lead drug Ojemda as the primary driver for the acquisition's strategic value.

来源: